Form 4: Vertex Pharmaceuticals Director Alan M. Garber Acquires Stock Options
SEC Form 4 Filing
Director Alan M. Garber acquired 3,142 stock options in Vertex Pharmaceuticals on May 1, 2024.
Summary
- On May 1, 2024, Alan M. Garber, a director of Vertex Pharmaceuticals, acquired 3,142 stock options.
- The exercise price of these options is $399.71.
- The options are fully vested and expire on April 30, 2034.
- Following the transaction, Garber directly owns 3,142 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's securities. It provides transparency into the trading activities of individuals with access to non-public information.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence by a company director.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of transaction: Alan M. Garber acquired stock options. |
| 04/30/2034 | Expiration date of the stock options. |
| 05/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.